Those involved have estimated that it will take at least $25 million dollars and 10 years to find a cure for PSP. That's the goal, reason and objective to be optimistic.
With so few people affected, it is estimated that only $3 million worth of research has been done in the last 15 years. The Peebler Research Foundation is dedicated to raising funds to improve the amount of research being done and will be working with the Society for Progressive Supranuclear Palsy to accomplish this goal.
The Society for Progressive Supranuclear Palsy Board
has named the new genetics program
The Charles D. Peebler Jr. PSP and CBD Genetics Program
This represents the first real step to unraveling this deadly disease.
Status of Phase I
CurePSP Genetics Program
There has been an explosion of reports of variants in the human genome that are associated with a myriad of diseases. There is every reason to believe that the same research will identify biological pathways that will predict not only the risk for PSP and CBD, but also the protein abnormalities that will be targets for prevention and treatment. Those are the reasons for the CurePSP Genetics Program that started in December 2007.
Phase I, the genome-wide analysis of patients with PSP and CBD, is now nearly done. We have competed tissue sampling of 1180 patients. The tissue analysis of an additional 120 patients will be completed this month. The final statistical data analysis will be completed before the end of this summer.
Neurologists have shown a great enthusiasm for the Program and provided us tissue samples from facilities through out the world. Phase I is under the direction of Gerard Schellenberg PhD, who is at the University of Pennsylvania, and includes an international consortium of investigators from the Mayo Clinic College of Medicine, the NIH, University of Pittsburg, University College of London UK, and the Lieberg and Phillips Universities in Germany.
As stated by Larry Golbe, M.D. CurePSP Director of Research, “Those results will likely point to anywhere from two to a few dozen areas that harbor mutations associated with PSP and CBD. Each area is likely to contain something like 10 to 100 known genes, maybe 10% of which will seem plausible as contributors to PSP or CBS. Those are called candidate genes. The next step, Phase II, will read the precise sequence of the genetic code in each of the candidate genes and compare them to the sequence of those genes in people without PSP. This will identify the specific genes necessary to cause PSP and CBD.”
Phase II will follow completion of this first stage of research, quickly. As specific genes are identified, we can characterize the biochemical pathways controlled by those genes, which will lead to providing ways to prevent, slow or cure PSP and CBD.
Advanced studies of this sort would have been technically impossible a decade ago. Even today, a genome-wide analysis of PSP and CBD would not have occurred without the foresight and encouragement of Chuck Peebler who provided the impetus and a major share of the necessary funding, through his family and the Peebler PSP Research Foundation.
Please use the Research Center and Education Center at the PSP.org site.